来自:中国糖尿病资讯网 编辑:editor|点击数:|2012-04-09
·糖尿病的胰岛素治疗·
李倩 张颖 张文礼 任轶飞 张鹏 朱剑 蒋兰兰 许向红 丁波 沈赟 苏晓飞 马建华
作者单位:210006南京医科大学附属南京第一医院内分泌科
通讯作者:马建华,E-mail:majianhua@china.com究
【摘要】目的比较应用微量注射泵与持续皮下泵输注胰岛素治疗高血糖患者的临床疗效和费用,为临床医生选择合适的降糖方案提供依据。方法选择住院高血糖患者,随机分为持续皮下泵胰岛素注射组(皮下泵组)和微量注射泵胰岛素注射组(静脉泵组)各120例,给予一定剂量的胰岛素治疗4h,观察两组降糖效果、胰岛素剂量、低血糖事件及费用情况。结果两组血糖下降差值及低血糖事件差异无统计学意义;静脉泵组所需的胰岛素量较少、费用较低,两组差异有统计学意义(P<0.05)。结论应用微量静脉泵输注胰岛素能够在一定时间内解除高血糖毒性,所需费用较低,低血糖事件也无明显增加,患者在住院期应用微量静脉泵注射胰岛素解除高血糖毒性是可以选择的方法之一。
【关键词】高血糖;微量泵;持续皮下泵;糖尿病,2型;胰岛素治疗
doi:10.3969/j.issn.1006-6187.2012.03.011
The clinical study on micro intravenous infusion pump and continuous subcutaneous infusion pump for insulin therapy in hyperglycemia patientsLI Qian, ZHANG Ying, ZHANG Wen-li, et al. Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006,China
Corresponding author: MA Jian-hua, E-mail: majianhua@china.com
【Abstract】ObjectiveTo compare the clinical effect and cost of micro intravenous infusion pump and continuous subcutaneous infusion pump for insulin therapy.MethodsTwo hundred and forty inpatients with hyperglycemia were rolled in this study. These patients were randomly divided into micro infusion syringe pump(MIP) group and continuous subcutaneous infusion(CSI) group and were given a certain dose of insulin for 4h.The collected data included the blood glucose, insulin dose, hypoglycemic events and cost of two groups.ResultsThere were no significant difference in blood glucose decrease and hypoglycemic event between the two groups, but the insulin dose and cost were significantly lower in the MIP group than those in the CSI group.ConclusionThe method with micro infusion pump in insulin therapy is an optional treatment for hyperglycemic patient for its effecacy and lower cost.
【Key words】 Hyperglycemia; Micro-infusion pump; Continuous subcutaneous infusion pump; Diabetes mellitus,type 2; Insulin therapy
版权所有:《中国糖尿病杂志》社 主管单位:中华人民共和国教育部 主办单位:北京大学
地址:北京市西城区大红罗厂街1号 邮编:100034 电话(传真):010-88505683
中国糖尿病杂志社版权所 京ICP备11029051号-1 Powered by JiuduCMS 技术支持:九度创想